Latest Breaking News On - ஆய்வகங்கள் ப்ரைவேட் - Page 2 : comparemela.com

Breckenridge Announces Final Approval of its ANDA for Asenapine Sublingual Tablets, 5 mg Strength (generic for Saphris®) News provided by Share this article Share this article BERLIN, Conn., March 8, 2021 /PRNewswire/ Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Asenapine Sublingual Tablets in 5mg strength (generic for Saphris ®). Breckenridge plans to launch this strength immediately. Breckenridge previously launched the product s 2.5mg and 10mg strengths and will now market all three strengths. This product was developed in collaboration with MSN Laboratories Private Limited. According to industry sales data, Saphris

Andhra pradeshRobert gasparinoLaboratories privateDrug administrationBreckenridge pharmaceutical incPrnewswire breckenridge pharmaceutical incBusiness developmentAbbreviated new drug applicationAsenapine sublingual tabletsTowa pharmaceuticalAssociate vice presidentBreckenridge pharmaceuticalMedical pharmaceuticalsHealth care amp hospitalsFda approvalஆந்திரா பிரதேஷ்